论文部分内容阅读
目前肺癌手术治疗仍是最主要方法之一。但术后的复发和转移,严重影响患者的术后生存期。而辅以术后化疗,效果并不理想。近年来,肿瘤免疫疗法的进展,为肿瘤综合治疗提供了新的希望。本文就肺癌手术治疗后,进一步将肿瘤浸润淋巴细胞(TIL)分离,进行体外培养、扩增及杀伤活性检测,并对术后患者回输 TIL 进行探讨。1 资料和方法1.1 一般资料本文选择1993年10月至1994年12月在本院手术治疗肺癌患者9例:其中男性8例,女性1例;年龄49～68岁。临床分期:Ⅲ_b6例,Ⅲ。3例。病理分型:腺癌7例,鳞癌2例。术前均未进行特殊治疗。
Lung cancer surgery is still one of the most important methods. However, postoperative recurrence and metastasis severely affect the patient’s postoperative survival period. With adjuvant chemotherapy, the effect is not ideal. In recent years, the progress of cancer immunotherapy has provided new hope for comprehensive treatment of tumors. In this paper, after surgical treatment of lung cancer, tumor-infiltrating lymphocytes (TIL) were further isolated, cultured in vitro, amplified and assayed for anti-inflammation activity, and TIL after transfusion was explored. 1 Materials and Methods 1.1 General Information In this paper, 9 patients with lung cancer were treated surgically from October 1993 to December 1994 in this hospital: 8 males and 1 female; aged 49-68 years. Clinical stage: III_b6 cases, III. 3 cases. Pathological type: 7 cases of adenocarcinoma, 2 cases of squamous cell carcinoma. No special treatment was performed before surgery.